Brief: Transcode Therapeutics Completes Phase 1A Trial With TTX-MC138 In Metastatic Disease At ESMO - SEC Filing
14/10/2025 13:19
Oct 14 (Reuters) - Transcode Therapeutics Inc RNAZ.O: TRANSCODE THERAPEUTICS INC - COMPLETES PHASE 1A TRIAL WITH TTX-MC138 IN METASTATIC DISEASE AT ESMO- SEC FILING TRANSCODE THERAPEUTICS INC - SAFETY PRIMARY ENDPOINT ACHIEVED IN PHASE 1A TRIAL - SEC FILING Source text: [ID:n0001104659-25-099029] Further company coverage: RNAZ.O
Recent news on Transcode Therapeutics
See all newsBrief: TransCode Therapeutics Appoints John Tattory As Interim CFO
Brief: Transcode Therapeutics Appoints Dr. Anna Moore As Chair Of Scientific Advisory Board
Brief: Transcode Therapeutics Inc - Enters Exclusive License Agreement With Unleash
Brief: Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026
Brief: Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors